BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
BioLineRx Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026
$1.98−0.03 (-1.49%)
Close on Oct 19, 2026
- Market cap
- $5.28B
- P/E (TTM)
- –
- Dividend yield
- –
BioLineRx Ltd. revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| U.S. [Member] | $1.18M | $13.98M | $190.00K | $0 | 100.0% | -91.6% |
| China [Member] | $0 | $14.96M | $4.61M | $0 | 0.0% | -100.0% |
From the segment and revenue-disaggregation notes of BioLineRx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.